Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1.2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API)

Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1.2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API)

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis Vol. 48; no. 4; pp. 1082 - 1089
Main Authors: BARMAN, Phil J, CHATFIELD, Marion J, CROWLEY, Elizabeth L, ECKERS, Christine, ELDER, David P, FRANCEY, Scott W, LAURES, Alice M.-F, WOLFF, Jean-Claude
Format: Journal Article
Language:English
Published: Amsterdam Elsevier 2008
Subjects:
Analysis
Analytical, structural and metabolic biochemistry
Biological and medical sciences
Fundamental and applied biological sciences. Psychology
General pharmacology
Medical sciences
Pharmacology. Drug treatments
Validation
Paroxetine
Serotonin
Impurity
Psychotropic
Sub-ppm impurity
HPLC chromatography
Reuptake inhibitor
Selective serotonin reuptake inhibitor
Pyridine derivatives
Toxin
Neurotoxicity
Mass spectrometry MS/MS
Technology transfer
Technology transfer to factory
Piperidine derivatives
Neurotoxin
Neurotransmitter
Development
Antidepressant agent
Environment
Active ingredient
Fluorine Organic compounds
LC-MS/MS assay
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0731-7085
1873-264X